Business Wire

CA-ESRI

Share
Esri Releases Updated Land-Cover Map with New Sets of Global Data

Governments and businesses across the world are pledging to adopt more sustainable and equitable practices. Many are also working to limit activities that contribute to climate change. To support these efforts, Esri , the global leader in location intelligence, in partnership with Impact Observatory and Microsoft, is releasing a globally consistent 2017–2021 global land-use and land-cover map of the world based on the most up-to-date 10-meter Sentinel-2 satellite data. In addition to the new 2021 data, 10-meter land-use and land-cover data for 2017, 2018, 2019, and 2020 is included, illustrating five years of change across the planet.

This digital rendering of earth's surfaces offers detailed information and insights about how land is being used. The map is available online to more than 10 million users of geographic information system (GIS) software through Esri's ArcGIS Living Atlas of the World , the foremost collection of geographic information and services, including maps and apps.

"Accurate, timely, and accessible maps are critical for understanding the rapidly changing world, especially as the effects of climate change accelerate globally," said Jack Dangermond, Esri founder and president. "Planners worldwide can use this map to better understand complex challenges and take a geographic approach to decisions about food security, sustainable land use, surface water, and resource management."

Esri released a 2020 global land-cover map last year as well as a high-resolution 2050 global land-cover map , showing how earth's land surfaces might look 30 years from now. With the planned annual releases, users will have the option to make year-to-year comparisons for detecting change in vegetation and crops, forest extents, bare surfaces, and urban areas.

These maps also provide insights about locations with distinctive land use/land cover, as well as human activity affecting them. National government resource agencies use land-use/land-cover data as a basis for understanding trends in natural capital, which helps define land-planning priorities and determine budget allocations.

Esri's map layers were developed with imagery from the European Space Agency (ESA) Sentinel-2 satellite, with machine learning workflows by Esri Silver partner Impact Observatory and incredible compute resources from longtime partner Microsoft. The Sentinel-2 satellite carries a range of technologies including radar and multispectral imaging instruments for land, ocean, and atmospheres, enabling it to monitor vegetation, soil and water cover, inland waterways, and coastal areas.

"World leaders need to set and achieve ambitious targets for sustainable development and environmental restoration," said Steve Brumby, Impact Observatory cofounder and CEO. "Impact Observatory [and] our partners Esri and Microsoft are once again first to deliver an annual set of global maps at unprecedented scale and speed. These maps of changing land use and land cover provide leaders in governments, industry, and finance with a new AI [artificial intelligence]-powered capability for timely, actionable geospatial insights on demand."

Esri and Microsoft have released this 10-meter-resolution time-series map under a Creative Commons license to encourage broad adoption and ensure equitable access for planners working to create a more sustainable planet. Users can manipulate the map layers and other data layers with GIS software to create more dynamic visualizations.

In addition to being freely available in ArcGIS Online as a map service, these resources are also available for download and viewing. To explore the new 2021 global land-use/land-cover map, visit livingatlas.arcgis.com/landcover .

About Impact Observatory

Impact Observatory develops AI-powered, on-demand, geospatial data that maps changing land use and land cover at unprecedented scale and speed. Impact Observatory provides world leaders in governments, industry, and finance with timely, actionable, data-driven insights for sustainability and environmental risk analysis. Impact Observatory is a U.S. technology company based in Washington, D.C.

About Esri

Esri, the global market leader in geographic information system (GIS) software, location intelligence, and mapping, helps customers unlock the full potential of data to improve operational and business results. Founded in 1969 in Redlands, California, USA, Esri software is deployed in more than 350,000 organizations globally and in over 200,000 institutions in the Americas, Asia and the Pacific, Europe, Africa, and the Middle East, including Fortune 500 companies, government agencies, nonprofits, and universities. Esri has regional offices, international distributors, and partners providing local support in over 100 countries on six continents. With its pioneering commitment to geospatial information technology, Esri engineers the most innovative solutions for digital transformation, the Internet of Things (IoT), and advanced analytics. Visit us at esri.com .

Copyright © 2022 Esri. All rights reserved. Esri, the Esri globe logo, ArcGIS, The Science of Where, esri.com, and @esri.com are trademarks, service marks, or registered marks of Esri in the United States, the European Community, or certain other jurisdictions. Other companies and products or services mentioned herein may be trademarks, service marks, or registered marks of their respective mark owners.

Link:

ClickThru

About Business Wire

Business Wire
Business Wire
101 California Street, 20th Floor
CA 94111 San Francisco

http://businesswire.com

Subscribe to releases from Business Wire

Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.

Latest releases from Business Wire

Sonrotoclax Data at ASH 2025 Confirm Foundational Potential Across B-cell Malignancies8.12.2025 00:00:00 CET | Press release

Novel BCL2 inhibitor sonrotoclax monotherapy demonstrates deep and durable clinical responses in R/R MCL and R/R CLLSonrotoclax in combination with BRUKINSA demonstrated rapid MRD negativity in treatment-naive CLL, regardless of high-risk features BeOne Medicines Ltd. (Nasdaq: ONC; HKEX: 06160; SSE: 688235), a global oncology company, today announced new data on sonrotoclax, a next-generation investigational BCL2 inhibitor, demonstrating meaningful clinical benefit as monotherapy and in combination across B-cell malignancies. These data were featured at the 67th American Society of Hematology (ASH) Annual Meeting & Exposition in Orlando, Florida. The five presentations highlight durable responses in heavily pretreated patients with relapsed/refractory (R/R) mantle cell lymphoma (MCL) and additional studies showing deep, rapid, and sustained undetectable minimal residual disease (uMRD) rates with sonrotoclax-based combinations in patients with treatment-naive chronic lymphocytic leukemi

Andersen Consulting tilføjer samarbejdsfirmaet Codezilla7.12.2025 21:19:00 CET | Pressemeddelelse

Andersen Consulting styrker sine kompetencer inden for digital transformation gennem en samarbejdsaftale med Codezilla, et firma med hovedsæde i Rumænien, der udvikler specialtilpasset software. Codezilla specialiserer sig i at udvikle skræddersyede softwareprodukter, der løser forretningsmæssige udfordringer gennem en tværfaglig tilgang, som kombinerer softwareudvikling med dybdegående marketingekspertise. Med over 30 år på markedet fungerer firmaet som implementerings- og digital konsulentressource for reklamebureauer, samtidig med at de arbejder med en bred kundebase, herunder virksomheder inden for sundhedssektoren og medicinsk udstyr. Codezillas interne teams strækker sig over teknik, design og strategi og leverer omnichannel-løsninger til både regionale og globale kunder. "Vi tror på, at fantastisk software er resultatet af solid ingeniørkunst og disciplineret eksekvering," udtaler Sebastian Doroftei, administrerende direktør for Codezilla. "Vores samarbejde med Andersen Consulti

Hemato-Oncology Trials: AOP Health Presents New Results at Top Congress ASH7.12.2025 17:00:00 CET | Press release

AOP Health continues to advance its clinical research program in myeloproliferative neoplasms, a special group of rare blood cancers. The company, specialized in rare diseases, presented the results of two scientific investigations at the 67th American Society of Hematology Association (ASH) Annual Meeting 2025 held in Orlando, FL, USA. The results provide new insights in treatment strategies. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20251207587915/en/ Dr. Martin Steinhart, CEO AOP Health; Photo credit: AOP Health/Studio Koekart ROP-ET and BESREMI PASS One of the clinical studies, ROP-ET, examined the use of ropeginterferon alfa-2b in people with essential thrombocythemia (ET), a disease in which the body produces too many platelets. The trial, a prospective, multicenter, single-arm phase III study, investigated the safety and efficacy of ropeginterferon alfa-2b in ET patients unable to receive available cytoreductive th

CoMotion GLOBAL 2025 Launches in Riyadh: Global Mobility Leaders Unite in Saudi Capital to Chart Urban Future7.12.2025 13:00:00 CET | Press release

Summit debuts Mayors in Motion initiative and CoMotion Urban Visionary Distinction as Riyadh showcases its rise as global mobility testbed Riyadh is rapidly becoming one of the world's most ambitious urban mobility laboratories, where next-generation technologies move from blueprint to real-world deployment on city streets at unprecedented scale. CoMotion GLOBAL 2025, the world's most influential gathering of urban mobility leaders, opens today in Riyadh for a three-day summit bringing together innovators from Africa, Asia, Europe, the Americas, and the Middle East. Running December 7-9, the event will explore how electrification, autonomy, AI-enabled transport, and giga-project urbanism are reshaping cities worldwide. The summit will spotlight everything from high-performance EVs and breakthrough autonomous fleets to emerging-market transport solutions and new mobility models, demonstrating how the Kingdom is opening new pathways for global mobility leadership. Strategic Partnerships

Deciphera Announces Oral Presentation of Positive Topline Results from Phase 2a Study of Sapablursen in Polycythemia Vera at the 67th American Society of Hematology (ASH) Annual Meeting6.12.2025 15:30:00 CET | Press release

Results from Phase 2a IMPRSSION study demonstrate sapablursen significantly reduced phlebotomy rate, controlled hematocrit and increased serum hepcidin Sapablursen was generally safe and well tolerated Results support further development of sapablursen in a Phase 3 study Deciphera Pharmaceuticals, a member of Ono Pharmaceutical Co., Ltd. (Headquarters: Osaka, Japan; President and COO: Toichi Takino; “Ono”), today announced the oral presentation of positive results from the Phase 2a IMPRSSION study of sapablursen in patients with polycythemia vera (PV) at the 67th American Society of Hematology (ASH) Annual Meeting, taking place December 6-9, 2025, in Orlando, FL. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20251206361611/en/ The results were presented by Ionis Pharmaceuticals, who discovered and developed sapablursen and conducted the IMPRSSION study. In March 2025, Ionis and Ono entered into a license agreement in which On

In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.

Visit our pressroom
World GlobeA line styled icon from Orion Icon Library.HiddenA line styled icon from Orion Icon Library.Eye